慢性骨髓增殖性肿瘤患者的淋巴增殖性疾病:一项系统综述
该系统综述纳入2005年1月以来发表的50篇文献、214例同时患Ph阴性骨髓增殖性肿瘤(MPN)和淋巴增殖性疾病(LPD)的患者个体数据。患者诊断MPN中位年龄67岁(26-94岁),44%为原发性血小板增多症、29%为真性红细胞增多症、23%为骨髓纤维化;半数在MPN诊断后中位72个月发生LPD,20%的LPD诊断先于或同时于MPN。LPD以惰性为主,尤其是慢性淋巴细胞白血病(CLL),侵袭性淋巴瘤和多发性骨髓瘤在MPN随访期间发生的LPD中占相当部分。
要点
- 214例MPN合并LPD患者中,CLL多见于PV患者且男性比例很高、MPN诊断年龄较大。
- 多发性骨髓瘤在PV患者中罕见,多见于不携带JAK2 V617F突变的女性患者。
- 基于46例有随访数据的病例,MPN诊断后中位生存期为96个月。
核心结论
- 该综述证实LPD是MPN患者病程中值得关注的临床事件,需要对照研究以更好识别LPD高风险个体、支持监测计划并避免可能促进LPD的治疗。
研究设计与样本
- 对2005年1月以来发表的文献进行范围综述,分析50篇文献中214例同时患MPN和LPD患者的单患者临床数据。
主要发现
- 患者诊断MPN时中位年龄67岁(26-94岁),44%为原发性血小板增多症、29%为真性红细胞增多症、23%为骨髓纤维化。
- 半数患者在MPN诊断后中位72个月发生LPD,20%的LPD诊断先于或同时于MPN。
- LPD以惰性为主,尤其是CLL;侵袭性淋巴瘤和多发性骨髓瘤在MPN随访期间发生的LPD中占相当部分。
- CLL多见于PV患者,与很高的男性-to-女性比例及MPN诊断时年龄较大相关。
- 多发性骨髓瘤在PV患者中罕见,多见于不携带JAK2 V617F突变的女性患者;基于46例有随访数据的病例,MPN诊断后中位生存期96个月。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with a Ph-negative myeloproliferative neoplasm (MPN) may harbor or develop lymphoproliferative disorders (LPD), however, the clinical and molecular determinants of MPN and LPD co-occurrence are still uncertain. To systematically pool the available knowledge, we conducted a scoping review of literature published since January 2005 and analyzed single-patient clinical data from 50 papers reporting 214 individuals harboring both MPN and LPD. Patients had been diagnosed essential thrombocythemia (44%), polycythemia vera (29%), or myelofibrosis (23%) at a median age of 67 years (26-94): half of them incurred a LPD after a median of 72 months from MPN diagnosis, while in 20% the LPD diagnosis was antecedent or synchronous. Patients mainly incurred indolent LPD, particularly chronic lymphocytic leukemia (CLL), while aggressive lymphomas and multiple myeloma were a relevant portion of the LPDs occurring in the follow-up of MPN. CLL was preferentially diagnosed in PV patients and was associated with a very high male-to-female ratio, as well as an older age at MPN diagnosis. On converse, multiple myeloma was rarely reported in PV patients and was preferentially diagnosed in female patients not harboring the JAK2 V617F mutation. Based on the 46 cases reporting follow-up data, median survival after MPN diagnosis was 96 months. This thorough review of published evidence confirms that LPD are relevant clinical events in the history of MPN patients. Controlled studies are needed to better refine individuals at higher risk of developing LPD, to support surveillance programs and to avoid therapies possibly favoring LPD.
引用
- Marchetti M, Carobbio A, Capitoni E, et al. Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review. Am J Hematol. 2018. PMID: 29377227. doi:10.1002/ajh.25049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。